Explore the PD-L1 Pathway

Building on the foundation of PD-L1 pathway inhibition

Genentech is continuing to advance the understanding of cancer immunotherapy by researching pathways that can be targeted simultaneously with the PD-L1/PD-1 pathway to address various immune escape mechanisms in cancer.

As a scientifically validated approach to reinvigorating the antitumor immune response, PD-L1 pathway inhibition has taken an important role in restoring a key part of the cancer immunity cycle.1

PD-L1 inhibition as key to cancer immunotherapy research

PD-L1=programmed death-ligand 1.

References

  1. Kim JM, Chen DS. Ann Oncol. 2016;27:1492-1504. PMID: 27207108